Translumina
Translumina is a privately held, Germany-headquartered manufacturer of interventional cardiovascular devices — drug eluting stents, drug eluting balloons, and PTCA balloons — selling to hospitals across 40+ countries via channel partners and direct operations in markets such as the UAE.
- Company typePrivate
- Founded2000
- HeadquartersHechingen, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Translumina does
Translumina is a privately held global manufacturer of interventional cardiovascular medical devices, headquartered in Hechingen, Germany, with manufacturing operations in Germany (Hechingen), the Netherlands (Helmond), and India (Dehradun), and approximately 600 employees worldwide. The company's product portfolio is concentrated in three categories used during percutaneous coronary interventions: drug eluting stents (permanent implantable scaffolds with anti-proliferative drug coatings), drug eluting balloons (for localized drug delivery without permanent implant), and PTCA balloons (for coronary artery dilation). Translumina's underlying technology platform includes proprietary drug application and coating methods, notably extended through the June 2023 acquisition of Netherlands-based Blue Medical Devices.
The company generates revenue through B2B hardware sales of cardiovascular devices to hospitals and healthcare providers, using quote-based enterprise pricing that is not publicly disclosed. Translumina's go-to-market combines 60+ channel partners across 40+ countries with direct operations in selected markets — most recently the UAE, where direct operations were launched in May 2024 — and acquired distribution assets including Munich-based Lamed GmbH (June 2023) in Germany. Manufacturing is certified to ISO 13485:2016 and ISO 9001:2015, and Translumina positions itself as India's largest domestic player in the coronary stents market. The company maintains an active sub-brand, TransAcademy, aimed at clinician education, and pursues a horizontal segmentation strategy targeting hospitals performing interventional cardiology.
Translumina firmographics
Firmographics- Name
- Translumina
- Legal name
- Translumina
- Website
- https://translumina.de
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Translumina is a privately held, Germany-headquartered manufacturer of interventional cardiovascular devices — drug eluting stents, drug eluting balloons, and PTCA balloons — selling to hospitals across 40+ countries via channel partners and direct operations in markets such as the UAE.
- Ownership category
- akta.pro rank
Translumina industry classification
Industry- Product category
- Interventional Cardiovascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)
- akta.pro secondary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
Keywords
Where Translumina is headquartered
LocationHeadquarters
- HQ city
- Hechingen
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
Translumina business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Cardiovascular Medical Devices Sales: Sale of interventional cardiovascular devices including drug eluting stents, drug eluting balloons, and PTCA balloons to hospitals and healthcare providers globally
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Translumina product offering
Product offeringCore offering
Translumina manufactures and sells interventional cardiovascular devices, specifically drug eluting stents, drug eluting balloons, and PTCA balloons, used by hospitals and healthcare providers in coronary and vascular interventions. The company runs three ISO 13485:2016 and ISO 9001:2015 certified manufacturing facilities in India, Germany, and the Netherlands, and distributes its products globally through 60+ channel partners across 40+ countries supplemented by direct operations in select markets.
Product overview
Translumina offers a unified portfolio of three core interventional cardiovascular device categories: Drug Eluting Stents (permanent implantable scaffolds with anti-proliferative drug coating), Drug Eluting Balloons (for localized drug delivery without permanent implant), and PTCA Balloons (for coronary artery dilation during angioplasty). These products work synergistically to address different stages and approaches to coronary intervention treatment. The company operates manufacturing facilities in India, Germany, and the Netherlands and has expanded through acquisitions of Blue Medical Devices (Netherlands, 2023) and Lamed GmbH (Germany, 2023).
Differentiator
Problem solved
Functional benefit
Brands
- TransAcademy: Educational/training platform mentioned on the website
Products and services
- Drug Eluting Stents State-of-the-art drug-eluting stents designed for cardiovascular care, featuring advanced drug-eluting technology to prevent restenosis and improve patient outcomes in coronary interventions. Sold to hospitals and healthcare providers performing interventional cardiology procedures.
- Drug Eluting Balloons Cutting-edge drug-eluting balloons for vascular treatment, enabling localized drug delivery during percutaneous interventions without permanent implant placement. Sold to hospitals and healthcare providers.
- PTCA Balloons Advanced coronary balloons for percutaneous transluminal coronary angioplasty (PTCA), designed to dilate narrowed coronary arteries during cardiovascular interventions. Sold to hospitals and healthcare providers performing angioplasty procedures.
Companies that use Translumina
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Translumina technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Translumina partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Blue Medical DevicescoreIn June 2023, Translumina acquired Netherlands-based Blue Medical Devices to incorporate its drug application technology into Translumina's product range. The acquisition enhances Translumina's portfolio of interventional cardiovascular devices, specifically expanding drug-coated balloons and other coronary interventions capabilities.
- Lamed GmbHcoreTranslumina acquired Munich-based Lamed GmbH, a vascular and cardiovascular products distributor, to expand its footprint in Germany. The deal aims to strengthen Translumina's presence in Europe's largest interventional cardiology market and leverage Lamed's extensive hospital network.
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
Translumina competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Major player in interventional cardiology with Promus DES and drug-eluting balloons. Direct competitor to Translumina in coronary stents and DEB.
- Abbott: Global leader in interventional cardiology with Xience drug-eluting stents serving as the gold standard. Directly competes with Translumina in coronary stent procurement at major hospitals worldwide.
- Medtronic: Major cardiovascular device manufacturer with Resolute DES family and broad interventional cardiology portfolio. Competes with Translumina across coronary intervention segments globally.
- MicroPort Scientific Corporation: Chinese-origin cardiovascular device company with coronary stents (Firehawk) and broader structural heart portfolio. Competes with Translumina in emerging markets and Europe.
- Terumo Corporation: Japanese medical device conglomerate with interventional cardiology offerings (including acquired assets from Abbott). Established incumbent in the same cardiovascular procedure suite Translumina serves.
Direct peers
- B. Braun: European-headquartered interventional cardiology competitor with drug-eluting stents (Coroflex) and DEB portfolio. Particularly relevant as Translumina has built manufacturing in Germany competing in B. Braun's home market.
- Sahajanand Medical Technologies: Indian domestic coronary stent manufacturer with Supraflex/Yukon DES lines. Most direct domestic competitor to Translumina in the Indian coronary stent market.
- Meril Life Sciences: Indian interventional cardiology and structural heart device maker with drug-eluting stents and balloons. Comparable Indian mid-cap competitor targeting both domestic and export markets.
- Lepu Medical: Chinese manufacturer of drug-eluting stents and balloons with global distribution. Comparable mid-sized Asian-origin competitor with cost-competitive manufacturing and expanding international reach.
Emerging players
- iVascular: European-headquartered emerging competitor in drug-eluting balloons and peripheral vascular intervention. Comparable in scale and category focus on DEB technology overlap with Translumina's Blue Medical portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Translumina social profiles
Digital presenceTranslumina compliance and trust
Trust signalCompliance2 records
Translumina financial estimates
Financial estimateRevenue estimate
Valuation estimate
Translumina leadership team
Management profileNumber of profiles
Translumina subsidiaries and ownership
Company hierarchySubsidiaries2 records
Translumina funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Translumina M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Translumina
What does Translumina do?
Translumina manufactures and sells interventional cardiovascular devices, specifically drug eluting stents, drug eluting balloons, and PTCA balloons, used by hospitals and healthcare providers in coronary and vascular interventions. The company runs three ISO 13485:2016 and ISO 9001:2015 certified manufacturing facilities in India, Germany, and the Netherlands, and distributes its products globally through 60+ channel partners across 40+ countries supplemented by direct operations in select markets.
Is Translumina a public or private company?
Translumina is a private company. It is classified as unknown and is currently operating.
When was Translumina founded?
Translumina was founded in 2000. It employs 11 to 50 people.
Where is Translumina based?
Translumina is headquartered in Hechingen, Germany, in the Europe region.
How does Translumina make money?
One revenue line is on record: cardiovascular Medical Devices Sales.
Who are Translumina's main competitors?
Broad incumbents on record are Boston Scientific, Abbott, Medtronic, MicroPort Scientific Corporation and Terumo Corporation. Direct peers are B. Braun, Sahajanand Medical Technologies, Meril Life Sciences and Lepu Medical. iVascular is listed as an emerging player.
Does Translumina have an API?
No public API is recorded for Translumina.
What industry is Translumina in?
Translumina's product category is Interventional Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.